Answers are grounded in this paper and cite their sources.
Purpose The purpose of this manuscript is to review evidence-based practices for the safe inpatient use of pulmonary arterial hypertension (PAH) medications and facilitate effective transitions of care. Summary Patients with PAH can present to the hospital with clinical conditions related to PAH, acute conditions unrelated to PAH, or complications of targeted PAH medications. Rapid triage and assessment of hospital capabilities pertaining to PAH medication use is essential to facilitate continued care or transfer to an expert PAH center. An assessment of hospital-specific capabilities should include the availability of specialists experienced in PAH, the formulary status of PAH medications, and clinician proficiency in the use of parenteral prostacyclin agents. Continuation or modification of PAH medications should be coordinated with the patient’s primary PAH specialist. The use of targeted medications for PAH should be guided by multidisciplinary policies with procedures to ensure safe practices and compliance with risk evaluation and mitigation strategy programs, where applicable. Coordination of medication access and facilitating safe transitions of care at hospital discharge is multifaceted as agents are specialized and some are only dispensed by specialty pharmacies. Conclusion Management of a patient’s PAH pharmacotherapies in the hospital setting should involve clinicians with expertise in the use of PAH targeted therapies, be guided by standardized medication-use procedures, and involve care coordination to facilitate safe hospital discharge.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: